Search results
Results from the WOW.Com Content Network
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
Stelazine (trifluoperazine) – an antipsychotic used in the treatment of psychotic disorders, anxiety, and nausea caused by chemotherapy [2] Strattera (atomoxetine) – a non-stimulant medication used to treat ADHD; Suboxone (buprenorphine/naloxone) - a partial opioid agonist used in the treatment of opioid use disorder
It is indicated in the treatment of schizophrenia and schizoaffective disorder. [14] It is marketed by Janssen Pharmaceuticals. [4] Paliperidone was approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia in December 2006, [4] and in the European Union in June 2007. [8]
Clozapine, sold under the brand name Clozaril among others, is a psychiatric medication and was the first atypical antipsychotic to be discovered. [6] It is primarily used to treat people with schizophrenia and schizoaffective disorder who have had an inadequate response to two other antipsychotics, or who have been unable to tolerate other drugs due to extrapyramidal side effects.
The primary treatment of schizoaffective disorder is medication, with improved outcomes using combined long-term psychological and social supports. [23] Hospitalization may occur for severe episodes either voluntarily or (if mental health legislation allows it) involuntarily.
FDA approved for bipolar disorder maintenance therapy, not for acute mood problems like depression or mania/hypomania. [10] The usual target dose is 100–200 mg daily, titrated to by 25 mg increments every 2 weeks. [11] Lamotrigine can cause Stevens–Johnson syndrome, a very rare but potentially fatal skin condition. [10] Carbamazepine
Lurasidone was approved in the United States for the treatment of schizophrenia in October 2010 [93] [94] and for the treatment of depressive episodes associated with bipolar I disorder in June 2013. [ 25 ] [ 27 ] [ 28 ] It received regulatory approval in the United Kingdom in September 2014.
Amisulpride is approved and used at low doses in the treatment of dysthymia and major depressive disorder. [10] [20] [11] [21] [22] [23] Whereas typical doses used in schizophrenia block postsynaptic dopamine D 2-like receptors and reduce dopaminergic neurotransmission, low doses of amisulpride preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and thereby disinhibit dopamine ...